Michael Feld Sells 74 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 74 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $151.94, for a total value of $11,243.56. Following the completion of the transaction, the executive vice president owned 21,159 shares in the company, valued at $3,214,898.46. This represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total value of $13,638.00.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $145.27 on Thursday. The company has a market capitalization of $41.36 billion, a price-to-earnings ratio of 23.70, a P/E/G ratio of 10.68 and a beta of 0.29. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The business’s 50-day moving average is $161.35 and its 200-day moving average is $182.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.56 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Brighton Jones LLC lifted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC lifted its holdings in Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank lifted its holdings in Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the last quarter. Marshall Wace LLP lifted its holdings in Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Becton, Dickinson and Company by 34.7% in the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD launched the BD® CentroVena One™ all?in?one central venous catheter insertion system — a first?of?its?kind commercial product that can drive adoption in acute care and supports BD’s interventional/vascular access growth story. BD CentroVena One launch
• Positive Sentiment: The Board declared a quarterly dividend of $1.05 (payable June 30), maintaining yield and signaling continued cash return to shareholders. That supports income-minded holders and underpins the stock’s defensive appeal. Dividend announcement
• Neutral Sentiment: BD’s latest quarter showed an EPS beat but a material revenue miss; FY?2026 EPS guidance (12.35–12.65) is roughly in line with consensus — mixed fundamentals that leave valuation and execution the focus. Quarterly results & guidance
• Neutral Sentiment: Market commentary is debating whether recent share weakness is a buying opportunity; some analysts maintain buy ratings while several have lowered targets, so sentiment is split. Is It Time To Reconsider BDX?
• Negative Sentiment: Revenue shortfall and subsequent analyst target cuts/“hold” adjustments have likely triggered selling — these are the primary near?term drivers of share weakness. Analyst coverage & price targets
• Negative Sentiment: Technical pressure: shares are trading below the 50? and 200?day moving averages, which can accelerate outflows from trend?sensitive funds. Stock technicals
• Negative Sentiment: A small insider sale (EVP sold 74 shares under a Rule 10b5?1 plan) was disclosed; the transaction is routine and pre?arranged but can be cited by short?term traders as a negative signal. Insider sale disclosure

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Jefferies Financial Group lowered their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a research note on Friday, April 10th. They issued a “neutral” rating and a $167.00 price target for the company. Finally, TD Cowen boosted their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Six research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $189.08.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.